Biogenic particle and biomarker flux from a mooring time-series at AWI HAUSGARTEN

Since 2000 long-term measurements of vertical particle flux have been performed with moored sediment traps at the long-term observatory HAUSGARTEN in the eastern Fram Strait (79°N/4°E). The study area, which is seasonally covered with ice, is located in the confluence zone of the northward flowing warm saline Atlantic water with cold, low salinity water masses of Arctic origin. Current projections suggest that this area is particularly vulnerable to global warming. Total matter fluxes and components thereof (carbonate, particulate organic carbon and nitrogen, biogenic silica, biomarkers) revealed a bimodal seasonal pattern showing elevated sedimentation rates during May/June and August/September. Annual total matter flux (dry weight, DW) at ~ 300 m depth varied between 13 and 32 g/m**2/a during 2000 and 2005. Of this total flux 6-13 % was due to CaCO3, 4-21 % to refractory particulate organic carbon (POC), and 3-8 % to biogenic particulate silica (bPSi). The annual flux of all biogenic components together was almost constant during the period studied (8.5-8.8 g/m**2/a), although this varied from 27 to 67 % of the total annual flux. The fraction was lowest in a year characterized by the longest duration of ice coverage (91 and 70 days for the calendar year and summer season, May-September, respectively). Biomarker analyses revealed that organic matter originating from marine sources was present in excess of terrigenious material in the sedimented matter throughout most of the study period. Fluxes of recognizable phyto- and protozooplankton cells amounted up to 60x106 m**2/d. Diatoms and coccolithophorids were the most abundant organisms. Diatoms, mainly pennate species, dominated during the first years of the investigation. A shift in the composition occurred during the last year when numbers of diatoms declined considerably, leading to a dominance of coccolithoporids. This was also reflected in a decrease in the sedimentation of bPSi. The sedimentation of biogenic matter, however, did not differ from the amount observed during the previous years. Among the larger organisms, pteropods at times contributed significantly to both the total matter and CaCO3, fluxes.

Aplicação de métodos combinados na conservação da qualidade de lichias ‘Bengal’

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Doença infecciosa bursal: estudo sobre amostras vacinais e de campo, imunidade materna e desafio com amostra muito virulenta do vírus.

As aves foram separadas em quatro grupos, dois vacinados e dois não vacinados no 1º dia de vida. As aves foram desafiadas no 1º,4º,7º,10º,13º,16º,19º e 22º dias de vida. A cada dia de desafio eram coletados e medidos, antes e depois, os seguintes itens do grupo: peso relativo da bolsa de Fabrício, diâmetro da bolsa, bolsa de Fabrício para exame histológico e soro para medir os anticorpos contra a DIB, através de Elisa e avaliação clínica da DIB. Os resultados mostraram uma queda de anticorpos sem diferença significativa entre aves vacinadas e não vacinadas. Analisando os diferentes resultados, foi estabelecido que um título de Elisa (log10) de 3,4, foi o ponto de corte entre aves saudáveis e aves doentes. Foram construídas equações de regressão, para o estabelecimento do melhor dia para a vacinação ou do título de Elisa (log10), que as aves podem ter numa determinada idade. Assim sendo, os pintos da Empresa A deveriam receber vacina contra a DIB a partir do 6º - 7º dia, e os da Empresa B deveriam receber a vacina entre o 11º-12º dia de idade. Com os resultados obtidos neste experimento fica claro que as aves não devem ser vacinadas no 1º dia de vida, que o esquema de vacinação das reprodutoras ocasiona diferenças na proteção da progênie e que não se deve aplicar o mesmo esquema de vacinação indiscriminadamente para todos os lotes de frangos.

Early embryonic death in mares: clinical and hormonal aspects

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides

PURPOSE: G protein-coupled receptor agonists are being used as radiolabeled vectors for in vivo localization and therapy of tumors. Recently, somatostatin-based antagonists were shown to be superior to agonists. Here, we compare the new [111In/68Ga]-labeled bombesin-based antagonist RM1 with the agonist [111In]-AMBA for targeting the gastrin-releasing peptide receptor (GRPR). EXPERIMENTAL DESIGN: IC50, Kd values, and antagonist potency were determined using PC-3 and HEK-GRPR cells. Biodistribution and imaging studies were done in nude mice transplanted with the PC-3 tumor. The antagonist potency was assessed by evaluating the effects on calcium release and on receptor internalization monitored by immunofluorescence microscopy. RESULTS: The IC50 value of [(nat)In]-RM1 was 14 +/- 3.4 nmol/L. [(nat/111)In]-RM1 was found to bind to the GRPR with a Kd of 8.5 +/- 2.7 nmol/L compared with a Kd of 0.6 +/- 0.3 nmol/L of [111In]-AMBA. A higher maximum number of binding site value was observed for [111In]-RM1 (2.4 +/- 0.2 nmol/L) compared with [111In]-AMBA (0.7 +/- 0.1 nmol/L). [(nat)Lu]-AMBA is a potent agonist in the immunofluorescence-based internalization assay, whereas [(nat)In]-RM1 is inactive alone but efficiently antagonizes the bombesin effect. These data are confirmed by the calcium release assay. The pharmacokinetics showed a superiority of the radioantagonist with regard to the high tumor uptake (13.4 +/- 0.8% IA/g versus 3.69 +/- 0.75% IA/g at 4 hours after injection. as well as to all tumor-to-normal tissue ratios. CONCLUSION: Despite their relatively low GRPR affinity, the antagonists [111In/68Ga]-RM1 showed superior targeting properties compared with [111In]-AMBA. As found for somatostatin receptor-targeting radiopeptides, GRP-based radioantagonists seem to be superior to radioagonists for in vivo imaging and potentially also for targeted radiotherapy of GRPR-positive tumors.

1-甲基-1,4,7,10-四氮杂环十二烷镧配合物的合成及晶体结构

合成了1-甲基-1,4,7,10-四氮杂环十二烷(L)配体。在乙腈中培养了La(L)(CH_3CN)-(H_2O)(CF_3SO_3)_3配合物单晶,测定了其红外光谱和质子核磁共振谱。用X射线衍射方法测定了配合物的晶体结构,该晶体属于单斜晶系,P2_1/n空间群,a=0.9700(2)nm,b=1.5966(2)nm,c=1.9085(1)nm,β=104.71(3)°,V=2.8588(50)nm~3。配合物中镧为9配位,其配位多面体为扭曲的单帽四方反棱柱体。

Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p

PURPOSE: Malignant glial brain tumors consistently overexpress neurokinin type 1 receptors. In classic seed-based brachytherapy, one to several rigid (125)I seeds are inserted, mainly for the treatment of small low-grade gliomas. The complex geometry of rapidly proliferating high-grade gliomas requires a diffusible system targeting tumor-associated surface structures to saturate the tumor, including its margins. EXPERIMENTAL DESIGN: We developed a new targeting vector by conjugating the chelator 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid to Arg(1) of substance P, generating a radiopharmaceutical with a molecular weight of 1,806 Da and an IC(50) of 0.88 +/- 0.34 nmol/L. Cell biological studies were done with glioblastoma cell lines. neurokinin type-1 receptor (NK1R) autoradiography was done with 58 tumor biopsies. For labeling, (90)Y was mostly used. To reduce the "cross-fire effect" in critically located tumors, (177)Lut and (213)Bi were used instead. In a pilot study, we assessed feasibility, biodistribution, and early and long-term toxicity following i.t. injection of radiolabeled 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid substance P in 14 glioblastoma and six glioma patients of WHO grades 2 to 3. RESULTS: Autoradiography disclosed overexpression of NK1R in 55 of 58 gliomas of WHO grades 2 to 4. Internalization of the peptidic vector was found to be specific. Clinically, the radiopharmeutical was distributed according to tumor geometry. Only transient toxicity was seen as symptomatic radiogenic edema in one patient (observation period, 7-66 months). Disease stabilization and/or improved neurologic status was observed in 13 of 20 patients. Secondary resection disclosed widespread radiation necrosis with improved demarcation. CONCLUSIONS: Targeted radiotherapy using diffusible peptidic vectors represents an innovative strategy for local control of malignant gliomas, which will be further assessed as a neoadjuvant approach.